A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults
A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults
The primary objective is to estimate the size of the GR270773 treatment effect on 28-day all-cause mortality for two doses of GR270773 versus placebo in adult subjects with suspected or confirmed Gram-negative severe sepsis. GR270773 will be administered as a three-day continuous intravenous infusion.
Inclusion criteria:
Exclusion criteria:
Note: Subjects with advanced directives prohibiting only chest compression (CPR) are eligible for the study.
Villa Sarmiento-Haedo, Buenos Aires 1706, Argentina
Ciudad de Buenos Aires, Argentina
Moron-Provincia de Buenos Aires, 1709, Argentina
Nedlands, Victoria 6009, Australia
Ostrava - Poruba, 708 52, Czechia
Haidari, 124 61, Greece
Rio, Patras, 265 00, Greece
Pokfulam, Hong Kong
Tuen Mun, New Territories, Hong Kong
Zrifin, 70300, Israel
Saint Petersburgh, 192242, Russia
Šempeter Pri Novi Gorici, Slovenia
Auckland Park, Johannesburg, 2006, South Africa
PO Medunsa, 0204, South Africa
Tarrasa, Spain
Tau-Yuan County, Taiwan